• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cellular immunology >Expression of the inflammatory chemokines CCL2, CCL5 and CXCL2 and the receptors CCR1-3 and CXCR2 in T lymphocytes from mammary tumor-bearing mice.
【24h】

Expression of the inflammatory chemokines CCL2, CCL5 and CXCL2 and the receptors CCR1-3 and CXCR2 in T lymphocytes from mammary tumor-bearing mice.

机译：炎性趋化因子CCL2，CCL5和CXCL2以及受体CCR1-3和CXCR2在乳腺荷瘤小鼠的T淋巴细胞中的表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chemokines and their receptors have been studied in several solid tumor models as mediators of inflammation. In turn, inflammation has been implicated in the promotion and progression of tumors, and as such, chemokines have been proposed as novel molecular targets for chemotherapy. While the expression of these molecules has been described in tumor cells, endothelial cells, macrophages and neutrophils, less attention has been paid to the expression profile of these molecules by T lymphocytes in the periphery or infiltrating the tumor. Using the D1-DMBA-3 murine mammary adenocarcinoma model, we aimed to better characterize the differential expression of chemokines and/or their receptors in the host and in the tumor microenvironment, and specifically, in the T cells of tumor-bearing mice compared to normal control animals. We found that T lymphocytes from tumor-bearing mice express the pro-inflammatory chemokines, CCL2, CCL5 and CXCL2, as well as the chemokine receptors, CCR1, CCR2, CCR3 and CXCR2.
机译：已经在几种实体肿瘤模型中研究了趋化因子及其受体作为炎症的介质。反过来，炎症已经牵涉到肿瘤的促进和发展，因此，已经提出趋化因子作为化学疗法的新型分子靶标。尽管已经在肿瘤细胞，内皮细胞，巨噬细胞和嗜中性粒细胞中描述了这些分子的表达，但是通过外周或浸润肿瘤的T淋巴细胞对这些分子的表达谱的关注较少。我们使用D1-DMBA-3鼠乳腺腺癌模型，旨在更好地表征趋化因子和/或其受体在宿主和肿瘤微环境中，特别是在荷瘤小鼠T细胞中与趋化因子和/或其受体的差异表达，与正常对照动物。我们发现来自荷瘤小鼠的T淋巴细胞表达促炎性趋化因子CCL2，CCL5和CXCL2，以及趋化因子受体CCR1，CCR2，CCR3和CXCR2。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号